Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine During Surgery for Glioblastoma
NCT04716699Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lidocaine Hydrochloride Injection, without epinephrine in glioblastoma (GBM), sponsored by University of California, Davis. Primary endpoint: Difference between the concentrations of lidocaine in the tumor tissue and in the blood at 4 hours. Started Jan 2021; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04716699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716699.